Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
British Journal of Dermatology2014Vol. 172(5), pp. 1395–1406
Citations Over TimeTop 10% of 2014 papers
Robert Bissonnette, Lars Iversen, Howard Sofen, C.E.M. Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, S.T. Rottinghaus, Huaming Tan, James Proulx, Hernán Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk
Abstract
Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients. Safety profiles were comparable in both the continuous treatment group and retreatment group. Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.
Related Papers
- → Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies(2016)31 cited
- → Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight(2017)13 cited
- → Associated Dermatoses and Triggering Factors in Psoriasis*(1974)18 cited
- → Concomitant Psoriasis and Allergic Contact Dermatitis: Coexistent Interrelated Clinical Entities(1991)
- → Review: Treatment of plaque psoriasis with an ointment formulation of the Januskinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. V1(2016)